A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma - ScienceDirect
Zevalin™ Y-90 Unit Dose Pig – Gamma Gurus
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial - Biology
ZEVALIN - ibritumomab tiuxetan Acrotech Biopharma LLC ----------
Ibritumomab tiuxetan (Zevalin) - Indications, Dosing, Side effects
Zevalin: Package Insert - Drugs.com
Ibritumomab - Zevalin® - GlobalRPH
NM Therapies Radiopharm - NMTCB Flashcards | Quizlet
The radio-labeled antibody 90 Y-ibritumomab tiuxetan (Zevalin) binds to... | Download Scientific Diagram
Ibritumomab tiuxetan
111In-ibritumomab tiuxetan, Zevalin
Schematic representation of Zevalin ® targeting a lymphoma B-cell with... | Download Scientific Diagram
Schematic representation of 90 Y-labelled Zevalin, consisting of the... | Download Scientific Diagram
Zevalin
![PDF] Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/87263c8f83aaeb3b62b21560d721f1e197bad948/3-Figure2-1.png "PDF] Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). | Semantic Scholar")
PDF] Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). | Semantic Scholar
High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment | Journal of Nuclear Medicine
Reference ID: 3366104
Zevalin
Schematic representation of 90 Y-labelled Zevalin, consisting of the... | Download Scientific Diagram
Y-90 Ibritumomab Tiuxetan
Cancers | Free Full-Text | Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels
Retreatment with 90Y-labelled ibritumomab tiuxetan in a patient with follicular lymphoma who had previously responded to treatment - The Lancet Oncology
90Y-Ibritumomab Therapy in Refractory Non-Hodgkin's Lymphoma: Observations from 111In-Ibritumomab Pretreatment Imaging | Journal of Nuclear Medicine
90Y-ibritumomab tiuxetan: Rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma - ScienceDirect
Consent for Y-90 Zevalin Radiation Therapy, #577240
STAR: Product Websites | Acrotech STAR
